Overview

A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder

Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Behavior dysregulation is commonly associated with people with autism spectrum disorder (ASD). Irritability is a major safety concern in adults with ASD. This study will assess the efficacy and safety of JZP541 in the treatment of adults with irritability associated with ASD.
Phase:
Phase 2
Details
Lead Sponsor:
Jazz Pharmaceuticals
Collaborator:
GW Research